The Experts below are selected from a list of 222 Experts worldwide ranked by ideXlab platform
S Hsu - One of the best experts on this subject based on the ideXlab platform.
-
Localized primary cutaneous Mycobacterium kansasii infection in an immunocompromised patient.
Journal of the American Academy of Dermatology, 1999Co-Authors: J Stengem, K K Grande, S HsuAbstract:Mycobacterium kansasii is a rare primary cutaneous pathogen, most commonly affecting persons exposed to contaminated water, particularly after local trauma. Most patients who present with localized primary cutaneous M kansasii infection are immunocompetent, whereas the majority of patients with disseminated or pulmonary infection are immunocompromised. We describe a primary cutaneous M kansasii infection in an iatrogenically immunosuppressed patient.
-
Localized primary cutaneous Mycobacterium kansasii infection in an immunocompromised patient.
Journal of the American Academy of Dermatology, 1999Co-Authors: J Stengem, Kimberly Grande, S HsuAbstract:Abstract Mycobacterium kansasii is a rare primary cutaneous pathogen, most commonly affecting persons exposed to contaminated water, particularly after local trauma. Most patients who present with localized primary cutaneous M kansasii infection are immunocompetent, whereas the majority of patients with disseminated or pulmonary infection are immunocompromised. We describe a primary cutaneous M kansasii infection in an iatrogenically immunosuppressed patient. (J Am Acad Dermatol 1999;41:854-6.)
Richard J. Wallace - One of the best experts on this subject based on the ideXlab platform.
-
AIDS-Related Mycobacterium kansasii Infection with Initial Resistance to Clarithromycin
Diagnostic microbiology and infectious disease, 1998Co-Authors: William Burman, Barbara L. Stone, B A Brown, Richard J. Wallace, Erik C. BöttgerAbstract:Clarithromycin is a promising drug for the treatment of Mycobacterium kansasii infection. We report a patient with AIDS and severe M. kansasii infection who had previously received a short course of clarithromycin for sinusitis. He had clinical failure of treatment using clarithromycin plus ethambutol, and the initial isolate was found to be highly resistant to clarithromycin. Nucleotide sequencing of the 23S rRNA gene of this isolate demonstrated a single base mutation at position 2058, the same as that found in clarithromycin-resistant Mycobacterium avium.
-
rifampin resistant Mycobacterium kansasii
Clinical Infectious Diseases, 1994Co-Authors: Richard J. Wallace, Chai H. Ahn, Denise Dunbar, Barbara A Brown, Grace O Onyi, Robbie Dunlap, David T MurphyAbstract:We identified 36 rifampin-resistant Mycobacterium kansasii isolates, including 17 (4%) of 464 isolates recovered in Texas between 1989 and 1992. Of 29 patients infected with rifampin-resistant M. kansasii whose history of medication was known, 90% had previously received rifampin, and 58% of these patients had been treated with one or two effective drugs. Thirty-two percent of rifampin-resistant isolates recovered since 1989 were from patients who were seropositive for human immunodeficiency virus (HIV) infection. Twenty courses of therapy with a four-drug regimen determined on the basis of in vitro susceptibilities were administered to 16 patients from whom rifampin-resistant isolates were recovered; the therapy did not include surgery. Sputum cultures converted to negative as the result of 90% of treatments (time to conversion: mean, 11 weeks; range, 4-20 weeks). Bacteriologic relapses occurred in four of five patients who withdrew from therapy after being culture negative for < or = 6 months of therapy and in one of 12 patients who were culture negative for at least 12 months of therapy (mean, 16.3 months). This study suggests that the prognosis for cure of infection due to rifampin-resistant M. kansasii with chemotherapy alone is excellent, although the number of cases appears to be increasing, in part because of the HIV disease epidemic.
David T Murphy - One of the best experts on this subject based on the ideXlab platform.
-
rifampin resistant Mycobacterium kansasii
Clinical Infectious Diseases, 1994Co-Authors: Richard J. Wallace, Chai H. Ahn, Denise Dunbar, Barbara A Brown, Grace O Onyi, Robbie Dunlap, David T MurphyAbstract:We identified 36 rifampin-resistant Mycobacterium kansasii isolates, including 17 (4%) of 464 isolates recovered in Texas between 1989 and 1992. Of 29 patients infected with rifampin-resistant M. kansasii whose history of medication was known, 90% had previously received rifampin, and 58% of these patients had been treated with one or two effective drugs. Thirty-two percent of rifampin-resistant isolates recovered since 1989 were from patients who were seropositive for human immunodeficiency virus (HIV) infection. Twenty courses of therapy with a four-drug regimen determined on the basis of in vitro susceptibilities were administered to 16 patients from whom rifampin-resistant isolates were recovered; the therapy did not include surgery. Sputum cultures converted to negative as the result of 90% of treatments (time to conversion: mean, 11 weeks; range, 4-20 weeks). Bacteriologic relapses occurred in four of five patients who withdrew from therapy after being culture negative for < or = 6 months of therapy and in one of 12 patients who were culture negative for at least 12 months of therapy (mean, 16.3 months). This study suggests that the prognosis for cure of infection due to rifampin-resistant M. kansasii with chemotherapy alone is excellent, although the number of cases appears to be increasing, in part because of the HIV disease epidemic.
J Stengem - One of the best experts on this subject based on the ideXlab platform.
-
Localized primary cutaneous Mycobacterium kansasii infection in an immunocompromised patient.
Journal of the American Academy of Dermatology, 1999Co-Authors: J Stengem, K K Grande, S HsuAbstract:Mycobacterium kansasii is a rare primary cutaneous pathogen, most commonly affecting persons exposed to contaminated water, particularly after local trauma. Most patients who present with localized primary cutaneous M kansasii infection are immunocompetent, whereas the majority of patients with disseminated or pulmonary infection are immunocompromised. We describe a primary cutaneous M kansasii infection in an iatrogenically immunosuppressed patient.
-
Localized primary cutaneous Mycobacterium kansasii infection in an immunocompromised patient.
Journal of the American Academy of Dermatology, 1999Co-Authors: J Stengem, Kimberly Grande, S HsuAbstract:Abstract Mycobacterium kansasii is a rare primary cutaneous pathogen, most commonly affecting persons exposed to contaminated water, particularly after local trauma. Most patients who present with localized primary cutaneous M kansasii infection are immunocompetent, whereas the majority of patients with disseminated or pulmonary infection are immunocompromised. We describe a primary cutaneous M kansasii infection in an iatrogenically immunosuppressed patient. (J Am Acad Dermatol 1999;41:854-6.)
Stephen J. Cavalieri - One of the best experts on this subject based on the ideXlab platform.
-
In vitro susceptibility of Mycobacterium kansasii to clarithromycin.
Antimicrobial agents and chemotherapy, 1992Co-Authors: J. R. Biehle, Stephen J. CavalieriAbstract:The MICs of the macrolide clarithromycin for 31 clinical isolates of Mycobacterium kansasii were determined by three different methods. The methods employed were the proportion resistance method on 7H10 agar, the radiometric (BACTEC) method, and the T100 method of datum analysis. All methods gave similar results. The MICs were in a narrow range from 0.16 to 0.50 microgram/ml, with the MICs for 90% of isolates tested of 0.50 microgram/ml for the agar dilution and radiometric methods and 0.37 microgram/ml for the T100 method. The MBCs were determined for nine representative isolates by the radiometric broth method. The MBCs were equal to the MICs for four isolates, and the MBCs were twofold higher than the MICs for five isolates. Killing of 99.9% of the bacterial population was achieved at a clarithromycin concentration of 2.0 micrograms/ml for all nine isolates tested.
